In this episode of MedTech Global Insights, we explore the critical role of the Health Sciences Authority (HSA) Authorized Representative for foreign medical device manufacturers entering Singapore. Choosing this local partner is more than an administrative task—it's a strategic decision that can determine your commercial success and flexibility in the market. We uncover the single most common and costly mistake companies make: appointing their distributor as their legal representative. This creates a significant conflict of interest and can lead to your product registration being held hostage, blocking your ability to adapt your commercial strategy. We discuss how selecting an independent, expert representative protects your assets and streamlines your path to market. **Case Study:** A promising European startup was locked out of the Singapore market for over a year and faced significant financial demands after a relationship with their distributor-representative soured. Find out how this happened and the steps you can take to avoid this critical pitfall. **Key Takeaways:** * Why is appointing your distributor as your HSA Authorized Representative a major commercial risk? * What does "license ownership" really mean in Singapore and how does it directly impact your business control? * What are the key differences between a passive Registrant and a strategic regulatory partner? * How can your Singapore HSA approval serve as a strategic springboard into other ASEAN markets? * What are the essential post-market surveillance duties your representative must be equipped to handle? * Why is it crucial that your representative is independent from your commercial and logistics partners? Contact us for a consultation at [email protected] or visit https://pureglobal.com/